Hikma Pharmaceuticals Overview

  • Year Founded
  • 1978

Year Founded

  • Status
  • Public

  • Employees
  • 9,400

Employees

  • Stock Symbol
  • HIK

Stock Symbol

  • Investments
  • 26

  • Share Price
  • $22.06
  • (As of Friday Closing)

Hikma Pharmaceuticals General Information

Description

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.

Contact Information

Website
www.hikma.com
Formerly Known As
Hikma Pharma
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 10 Portman Square
  • London W1H 6AZ
  • England, United Kingdom
+44 020
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Distributors (Healthcare)
Stock Exchange
LON
Vertical(s)
Corporate Office
  • 10 Portman Square
  • London W1H 6AZ
  • England, United Kingdom
+44 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hikma Pharmaceuticals Stock Performance

As of 20-Nov-2026, Hikma Pharmaceuticals’s stock price is $22.06. Its current market cap is $4.57B with 207M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$22.06 $22.18 $15.79 - $23.67 $4.57B 207M 513K $1.77

Hikma Pharmaceuticals Financials Summary

As of 30-Jun-2026, Hikma Pharmaceuticals has a trailing 12-month revenue of $3.42B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 5,591,490 5,932,545 6,591,083 6,076,406
Revenue 3,419,000 3,349,000 3,127,000 2,875,000
EBITDA 859,000 813,000 719,000 538,000
Net Income 387,000 402,000 359,000 190,000
Total Assets 5,830,000 5,671,000 5,133,000 4,680,000
Total Debt 1,957,000 1,604,000 1,306,000 1,191,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hikma Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hikma Pharmaceuticals‘s full profile, request access.

Request a free trial

Hikma Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and
Other Pharmaceuticals and Biotechnology
London, United Kingdom
9,400 As of 2025

Mumbai, India
 

Montreal, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hikma Pharmaceuticals Competitors (28)

One of Hikma Pharmaceuticals’s 28 competitors is Lupin, a Corporation company based in Mumbai, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lupin Corporation Mumbai, India
Knight Therapeutics Corporation Montreal, Canada
Taro Pharmaceutical Industries Corporate Backed or Acquired Haifa Bay, Israel
Dr. Reddy's Corporation Hyderabad, India
Sandoz Corporation Basel, Switzerland
You’re viewing 5 of 28 competitors. Get the full list »

Hikma Pharmaceuticals Patents

Hikma Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20100125051-A1 Parenteral formulations comprising sugar-based esters and ethers Active 19-Nov-2008
US-8541360-B2 Parenteral formulations comprising sugar-based esters and ethers Active 19-Nov-2008

Hikma Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hikma Pharmaceuticals Investments & Acquisitions (26)

Hikma Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Takeda Pharmaceutical (Portfolio of Pharmaceutical Products). The deal was made on 31-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Takeda Pharmaceutical (Portfolio of Pharmaceutical Products) 31-Dec-2025 Corporate Asset Purchase Buildings and Property
Novugen (Kinase Inhibitor Medication for Cancer) 17-Apr-2025 Corporate Asset Purchase Buildings and Property
Xellia Pharmaceuticals (US Finished Dosage Form Business and Assets) 10-Sep-2024 Merger/Acquisition Pharmaceuticals
Rakuten Medical 06-Mar-2024 Later Stage VC Drug Discovery
Custopharm 21-Apr-2022 Merger/Acquisition Pharmaceuticals
You’re viewing 5 of 26 investments and acquisitions. Get the full list »

Hikma Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

28.62 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Hikma Pharmaceuticals’s complete esg history, request access »

Hikma Pharmaceuticals Exits (4)

Hikma Pharmaceuticals’s most recent exit was on 17-Sep-2014 from Pharmaceuticals Manufacturing Facilities in Bedford. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Pharmaceuticals Manufacturing Facilities in Bedford 17-Sep-2014 Completed
Ben Venue Laboratories 15-Jul-2014 Completed
HikmaCure 18-Sep-2013 Completed
  • 2 buyers
Unimark Remedies 15-Apr-2011 Corporate Completed
To view Hikma Pharmaceuticals’s complete exits history, request access »

Hikma Pharmaceuticals Affiliates

Subsidiaries (4)

Name Industry Location Year Founded
Hikma France Puteaux, France 2021
Hikma Ventures London, United Kingdom 2015
ribosepharm Grafelfing, Germany 1983
Thymoorgan Vienenburg, Germany 1980

Hikma Pharmaceuticals FAQs

  • When was Hikma Pharmaceuticals founded?

    Hikma Pharmaceuticals was founded in 1978.

  • Where is Hikma Pharmaceuticals headquartered?

    Hikma Pharmaceuticals is headquartered in London, United Kingdom.

  • What is the size of Hikma Pharmaceuticals?

    Hikma Pharmaceuticals has 9,400 total employees.

  • What industry is Hikma Pharmaceuticals in?

    Hikma Pharmaceuticals’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Hikma Pharmaceuticals a private or public company?

    Hikma Pharmaceuticals is a Public company.

  • What is Hikma Pharmaceuticals’s stock symbol?

    The ticker symbol for Hikma Pharmaceuticals is HIK.

  • What is the current stock price of Hikma Pharmaceuticals?

    As of 20-Nov-2026 the stock price of Hikma Pharmaceuticals is $22.06.

  • What is the current market cap of Hikma Pharmaceuticals?

    The current market capitalization of Hikma Pharmaceuticals is $4.57B.

  • What is Hikma Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Hikma Pharmaceuticals is $3.42B.

  • Who are Hikma Pharmaceuticals’s competitors?

    Lupin, Knight Therapeutics, Taro Pharmaceutical Industries, Dr. Reddy's, and Sandoz are some of the 28 competitors of Hikma Pharmaceuticals.

  • What is Hikma Pharmaceuticals’s annual earnings per share (EPS)?

    Hikma Pharmaceuticals’s EPS for 12 months was $1.77.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process